The UK's medicines watchdog has issued a critical 'red flag' warning to users of the type 2 diabetes medication Mounjaro, following reports of severe and potentially life-altering side effects.
The Medicines and Healthcare products Regulatory Agency (MHRA) has released a new safety alert for the drug, also known by its generic name tirzepatide. The alert highlights an established link between the medication and severe gastrointestinal issues, including gastroparesis (stomach paralysis) and intestinal obstructions.
Recognising the Dangerous Symptoms
Patients taking Mounjaro are being urgently advised to be vigilant for a specific set of symptoms that could indicate these serious conditions. The key warning signs include:
- Persistent and severe nausea and vomiting
- Intense abdominal pain or discomfort
- Feeling full after eating only a small amount of food
- Bloating that does not subside
The MHRA stresses that anyone experiencing these symptoms should seek immediate medical attention and inform their healthcare professional that they are taking Mounjaro.
The Mechanism of the Problem
Mounjaro, manufactured by pharmaceutical giant Eli Lilly, works by mimicking hormones that help regulate blood sugar and slow down digestion. This very mechanism, which promotes a feeling of fullness, is believed to be the cause of the dangerous slowdown or complete halt of food moving through the stomach and intestines in some patients.
These conditions, if left untreated, can lead to severe complications, requiring hospitalisation and potentially surgery.
Official Guidance and Drug Availability
It is crucial to note that Mounjaro is currently licensed in the UK solely for the treatment of type 2 diabetes. Its use as a weight-loss treatment is not officially approved, though it is sometimes prescribed 'off-label' for this purpose.
The MHRA continues to monitor the situation closely and advises all healthcare professionals to report any suspected adverse reactions through their Yellow Card scheme. Patients are strongly cautioned against stopping their medication without first consulting their doctor, but must be aware of these new potential risks.
